Study S000590

A Phase 1, Open-label Study to Compare the Pharmacokinetics and Pharmacodynamics of Warfarin and Esmolol in the Absence and Presence of MEDI0382 in Healthy Subjects

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

ClinicalTrials.gov record

Registration

Registration: NCT03347968
Study type: INTERVENTIONAL
Allocation: NON_RANDOMIZED
Phase: PHASE1
Masking: NONE
Status: COMPLETED
Enrollment: 22
Start: 2017-11-27
Primary completion: 2018-04-09
Lead sponsor: MedImmune LLC
Conditions: Healthy Volunteers
Interventions: BIOLOGICAL:MEDI0382; DRUG:Warfarin; DRUG:Esmolol
Results posted: FALSE

Registered primary outcomes

Maximum international normalized ratio (INRmax) [Days 2-8 and Days 27-33]
Change in heart rate from resting after a 9-minute excercise treadmill test (Bruce Protocol, first 3 stages) [Days 1 and 26]

Linked records (1)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

Record	Title	Year	Design	Identifiers	Link basis
R0053137	1030-P: Effect of MEDI0382 on the Pharmacodynamics and Pharmacokinetics of Warfarin or Esmolol in Healthy Volunteers H. Coleman, Diabetes	2019	Other trial	DOI	cites ClinicalTrials.gov:NCT03347968